Unlearn.AI

Ready to help revolutionize #medicine with #AI? Explore our open positions and join us in transforming the future of #healthcare: https://lnkd.in/gqkVbQte 🚀

"...The power of AI lies in its ability to reliably gauge the relative impact of multiple pieces of (occasionally conflicting) information to the clinical trajectory of a particular person, pulling the signal from the noise." — Jess Ross, Senior Government Affairs Lead at Unlearn, in the Managed Healthcare Executive article, "Digital Twins Could Be Crystal Balls of Healthcare" by Jared Kaltwasser 🔮 https://lnkd.in/dhBApiBG

"Digital twins are the future of medicine. They basically replace our entire medical system; you basically turn medicine into a predictive science, you run experiments, and you optimize patients' treatments" — Charles Fisher in the ZDNET article, "How digital twins could save time, money, and lives in developing prescription drugs" by Tiernan Ray 🚀 https://lnkd.in/gEUdcCVK

Join our team at #DPHARM2024 to explore the Unlearn Platform and discover how we’re helping leading pharma companies optimize #clinicaltrials using participants’ #digitaltwins. Don’t miss the opportunity to see this powerful first-of-its-kind tool in action—enhancing trial efficiency, precision, and delivering patient-specific insights into drug effectiveness. 🗓️ Schedule a time here: https://bit.ly/47bEX4K ——— Andrew Stelzer; Steven Herne; Anurag Kulkarni

🔊 Uninformative and noisy clinical outcomes? We can fix that. 📲 Get in touch with our team to learn how we can enhance your trials: https://bit.ly/473ZSa1

Deloitte's 2024 annual report, ‘Unleash AI’s Potential,’ recognizes Unlearn’s AI-powered solution leveraging patients’ #digitaltwins to reduce control arm sizes by ~20-50%—accelerating #clinicalresearch and enabling more trial participants to receive the experimental treatment. 🔗 https://bit.ly/4dDwJVq

“What sets our model apart is how we’ve tailored our approach to predicting disease progression over time...Our models are specifically designed to predict changes in disease, utilizing novel architectures that are well-suited for this purpose…By offering these advanced AI-driven models, we provide our clients with a broader lens through which they can view their clinical research, enabling insights that might otherwise be inaccessible.” – Steven Herne Thanks to NeurologyLive and Marco Meglio for featuring Unlearn 🚀 Read now: https://lnkd.in/gepwrCek

“If we really want #AI to have an impact on #drugdevelopment, we’re going to need to invite more AI researchers into the drug development process.” - Charles Fisher at the FDA/Clinical Trials Transformation Initiative (CTTI) workshop, ‘AI in Drug & Biological Product Development.’ Watch the recording here: https://lnkd.in/gyhqUBgD 🚀

Participants’ #digitaltwins can cut control arm sizes by up to 33% in Alzheimer’s disease #clinicaltrials, allowing more patients to receive the experimental treatment while helping to accelerate the development of new treatments. 🚀 Thanks to Brian K. Buntz and Drug Discovery & Development for featuring our founder and CEO, Charles Fisher. https://lnkd.in/gs8kspQW

🌐 According to the World Health Organization, major depressive disorder impacts approximately 280 million people globally, while schizophrenia affects about 24 million. To accelerate #clinicaldevelopment and bring new treatments to patients faster, we launched #DigitalTwin Generators for both #schizophrenia and #majordepressivedisorder last month. Explore them here: https://lnkd.in/ghYgWZxv